Estrogen and progestin receptors in human uterus: reference ranges of clinical conditions
Observational
OA: closed
CC0
⤵ 15 in-corpus citations
AI-generated summary
This study determined estrogen and progestin receptor levels and affinities in 319 human uteri, establishing reference ranges and finding variations with age and menstrual cycle phase.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
Estrogen receptor (ER) and progestin receptor (PR) levels and their respective dissociation constants (Kd) were determined by titration assay and Scatchard analyses in 319 human uteri. Levels of receptors were neither age nor uterine weight dependent. ER was higher in postmenopausal patients while PR levels were lower in women under 25 years of age. ER ranged from undetectable to 560 fmol/mg cytosol protein (mcp) while PR levels were generally 10-fold greater with a mean of 791 fmol/mcp. The mean of the Kd of ER was 4.0 X 10(-10) M while that for the PR was 9.2 X 10(-10) M. Receptor levels were not correlated with their respective Kd values nor with the Kd of the other receptor; therefore ligand affinities were not receptor concentration dependent. A population of patients was identified (12.5% of the total) in which the ER levels were undetectable while their corresponding PR ranged from 38 to 2,100 fmol/mcp. This suggests the existence of a type of PR which may not require ER for its expression and is independent of the phase of the cycle. Both ER and PR content were significantly elevated in the proliferative phase of the cycle. Evaluation of results as a function of histopathological features showed no relationship between the ER and PR of patients with anovulatory bleeding versus pathology. Uteri with leiomyomas contained ER and PR at levels comparable to those of histologically normal uteri. Adenomyosis patients tended to have lower ER and higher PR levels than the normal uteri. Reference ranges have been established for these receptors in uteri as a corollary to studies of these proteins in endometrial cancer.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (2-hop)
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]
Cited by (15)
- Effects of a Levonorgestrel-Releasing Intrauterine System on the Expression of Steroid Receptor Coregulators in Adenomyosis 2015
- Identification of displaced endometrial glands and embryonic duct remnants in female fetal reproductive tract: possible pathogenetic role in endometriotic and pelvic neoplastic processes 2012
- Effectiveness of the levonorgestrel-releasing intrauterine system in the treatment of adenomyosis diagnosed and monitored by magnetic resonance imaging 2007
- Therapeutic options for adenomyosis: a review 2006
- Adenomyosis: the pathophysiology of an oestrogen-dependent disease 2006
- Adenomyosis 2003
- Pathophysiology of adenomyosis 1998
- Adenomyosis, Leiomyomata, and Pelvic Pain 1998
- Estrogen and progesterone receptors of adenomyosis in postmenopausal breast cancer patients treated with tamoxifen 1998
- Treatment of adenomyosis-associated menorrhagia with a levonorgestrel-releasing intrauterine device 1997
- An effective minimally invasive method of treating adenomyosis by interstitial laser photocoagulation with the KTP laser 1997
- Treatment of adenomyosis-associated menorrhagia levonorgestrel-releasing intrauterine device with a 1997
- Adenomyosis 1995
- Evidence for estrogen synthesis in adenomyotic tissues 1993
- Adenomyosis: current perspectives 1989
Source provenance
- europepmc
- last seen: 2026-10-14T06:08:39.101224+00:00
- openalex
- last seen: 2026-06-04T00:00:01.174412+00:00
- pubmed
- last seen: 2026-10-08T21:39:27.130015+00:00
License: CC0
· commercial use OK